Transcriptional analysis of tumor-specific T-cell responses in cancer patients

Critical Reviews in Immunology

Volumn 22, Issue 5-6, 2002, Pages 449-462

  Nagorsen, Dirk ^a   Wang, Ena ^a   Marincola, Francesco M ^a   Even, Jos ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

cDNA microarrays; qRT PCR; Specific T cells; TCR repertoire analysis

Indexed keywords

BETA ACTIN; CD27 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; HLA ANTIGEN; MESSENGER RNA; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ASPIRATION BIOPSY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; EXPRESSED SEQUENCE TAG; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LASER; MEMORY CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC;

EID: 0038330610     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411(6835):380-384.
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-365.
3. Boon T, Coulie PG, van den Eynde, B. Tumor antigens recognized by T cells. Immunol Today 1997; 18:267.
4. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-4757.
5. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/ MelanA. Cancer J Sci Am 1997; 3:37-44.
6. Rosenberg SA, Yang JC, Schwartzentruber D, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dufour E, Schwartzberg L, Spiess P, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-327.
7. Rosenberg SA, Yanelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and IL-2. J Natl Cancer Inst 1994; 86:1159-1166.
8. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2(4):293-299.
9. Nielsen MB, Marincola FM. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother Pharmacol 2000; 46 Suppl:S62-66.
10. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
11. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB.PC: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138.
12. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968; 14(2):181-196.
13. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM. Functional heterogeneity of vaccine-induced CD8+ T-cells. J Immunol 2002; 168(11):5933-5942.
14. Herr W, Schneider J, Lohse AW, Meyer zum Bueschenfelde KH, Wolfel T. Detection and quantification of blood-derived CD8+T lymphocytes secreting TNFalpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996; 191:131-143.
15. Scheibenbogen C, Lee KH, Mayer S, Stefanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U. A sensitive Elispot assay for detection of CD8+ lymphocytes specific for HLA class I-peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3:221-226.
16. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995; 181(1):45-54.
17. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Wolfel T, Eggermont AM, Keilholz U. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 2000; 244(1-2):81-89.
18. Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E, Scheibenbogen C. Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. J Immunol Methods 2001; 251(1-2):101-108.
19. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998; 212:89.
20. Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltenyi S, Radbruch A, Assenmacher M, Schmitz J. Enrichment and detection of live antigen-specific CD4 and CD8 T cells based on cytokine secretion. Eur J Immunol 1999; 29:4053-4059.
21. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Lienard D, Lejeune F, Cerottini JC, Romero P. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001; 166(12):7634-7640.
22. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274(5284):94-96.
23. Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002; 2(4):263-272.
24. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163(11):6292-6300.
25. Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, Kammula U, Rosenberg SA, Marincola FM. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 2000; 165(4):2287-2296.
26. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998; 4(5):316-323.
27. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756-2765.
28. Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000; 87:391-398.
29. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000; 23(2):275-281. [Erratum appears in J Immunother 2000; 23(4):509.]
30. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18(23):3964-3973.
31. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-6458.
32. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93:243-251.
33. Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 2001; 69:937-943.
34. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5(6):677-685.
35. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9):3102-3108.
36. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6(3):829-837.
37. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19(18):3836-3847.
38. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997; 186(9):1407-1418.
39. + T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98:754-761.
40. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401(6754):708-712.
41. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410(6824):106-111.
42. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135:2865-2875.
43. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol. 1999; 163:6867-6875.
44. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6:986-994.
45. Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 1997; 210:195-203.
46. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann C. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time TR-PCR technology. J Immunol Methods 2000; 246:79-90.
47. Yin JL, Shackel NA, Zekry A, McGuinness PH, Richards C, Putten KV, McCaughan GW, Eris JM, Bishop GA. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 2001; 79(3):213-221.
48. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000; 92:1336-1344.
49. Monsurro V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001; 166:5817-5825.
50. Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, McGhee JR. Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Int Immunol 1994; 6(1):11-19.
51. Favre N, Bordmann G, Rudin W. Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RT-PCR. J Immunol Methods 1997; 204(1):57-66.
52. Kelso A, Groves P, Ramm L, Doyle AG. Single-cell analysis by RT-PCR reveals differential expression of multiple type 1 and 2 cytokine genes among cells within polarized CD4+ T cell populations. Int Immunol 1999; 11(4):617-621.
53. Kelso A, Costelloe EO, Johnson BJ, Groves P, Buttigieg K, Fitzpatrick DR. The genes for perforin, granzymes A-C and IFN-gamma are differentially expressed in single CD8(+) T cells during primary activation. Int Immunol 2002; 14(6):605-613.
54. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science 1996; 274:998-1001.
55. Ohnmacht GA, Wang E, Mocellin S, Abad A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM. Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001; 167(3):1809-1820.
56. Mocellin S, Ohnmacht GA, Wang E, Marincola FM. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 2001; 93:236-242.
57. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000; 18(4):457-459.
58. Wang E, Marincola FM. Amplification of small quantities of mRNA for expression analysis. In: Bowtell D, Sambrook J, editors. DNA microarrays. A molecular cloning manual. New York: Cold Spring Harbor Laboratory Press, 2002: 204-213.
59. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334(6181):395-402.
60. Lefranc MP, Lefranc G. The T cell receptor facts book. London: Academic Press, 2001.
61. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996; 272(5269):1755-1762.
62. Baccala R, Gonzalez-Quintial R, Kono DH, Theofilopoulos AN. Multiprobe RNase protection assay and sequence enrichment nuclease assay for TCR analysis. In: Oksenberg JR, editor. The antigen T cell receptor: selected protocols and applications. New York: Chapman & Hall, 1997: 86-144.
63. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligodonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153(6):2807-2818.
64. Cochet M, Pannetier C, Regnault A, Darche S, Leclerc C, Kourilsky P. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol 1992; 22(10):2639-2647.
65. Hingorani R, Choi IH, Akolkar P, Gulwani-Akolkar B, Pergolizzi R, Silver J, Gregersen PK. Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J Immunol 1993; 151(10):5762-5769.
66. Gorski J, Yassai M, Zhu X, Kissela B, Kissella B [corrected to Kissela B, Keever C, Flomenberg N]. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994; 152(10):5109-5119.
67. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995; 16(4):176-181.
68. Schwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C, Kourilsky P, Even J. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997; 158(9):4493-4499.
69. Dietrich PY, Caignard A, Lim A, Chung V, Pico JL, Pannetier C, Kourilsky P, Hercend T, Even J, Triebel F. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 1994; 84(8):2815-2820.
70. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, Metcalf JA, Walker RE, Falloon J, Baseler M, Feuerstein I, Masur H, Lane HC. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3(5):533-540.
71. Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C, Karmochkine M, Raguin G, Autran B, Debre P. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4(2):215-221.
72. Maini MK, Wedderburn LR, Hall FC, Wack A, Casorati G, Beverley PC. A comparison of two techniques for the molecular tracking of specific T-cell responses; CD4+ human T-cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+ population. Immunology 1998; 94(4):529-535.
73. Prevost-Blondel A, Chassin D, Zeliszewski D, Dorval I, Sterkers G, Pannetier C, Guillet JG. Preferential usage of the T-cell receptor by influenza virus hemagglutinin-specific human CD4+ T lymphocytes: in vitro life span of clonotypic T cells. J Virol 1995; 69(12):8046-8050.
74. Lim A, Trautmann L, Peyrat MA, Couedel C, Davodeau F, Romagne F, Kourilsky P, Bonneville M. Frequent contribution of T cell donotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol 2000; 165(4):2001-2011.
75. Andrews DM, Leary CP, Hishii M, Shen J, Kurnick JT. Use of single stranded conformational polymorphism (SSCP) for analysis of the T cell receptor. In: Oksenberg JR, editor. The antigen T cell receptor: selected protocols and applications. New York: Chapman & Hall, 1997:373-406.
76. Wack A, Montagna D, Dellabona P, Casorati G. An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. J Immunol Methods 1996; 196(2):181-192.
77. Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161(8):4183-4194.
78. Lim A, Toubert A, Pannetier C, Dougados M, Charron D, Kourilsky P, Even J. Spread of clonal T-cell expansions in rheumatoid arthritis patients. Hum Immunol 1996; 48(1-2):77-83.
79. Guillet M, Sebille F, Soulillou J. TCR usage in naive and committed alloreactive cells: implications for the understanding of TCR biases in transplantation. Curr Opin Immunol 2001; 13(5):566-571.
80. Guillet M, Brouard S, Gagne K, Sebille F, Cuturi MC, Delsuc MA, Soulillou JP. Different qualitative and quantitative regulation of V beta TCR transcripts during early acute allograft rejection and tolerance induction. J Immunol 2002; 168(10):5088-5095.
81. Jäger E, Hohn H, Necker A, Forster R, Karbach J, Freitag K, Neukirch C, Castelli C, Salter RD, Knuth A, Maeurer MJ. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer 2002; 98(3):376-388.
82. + T cells in melanoma patients. J Immunol 2000; 165:533.
83. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270 (5235):467-470.
84. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, Xiao H, Merril CR, Wu A, Olde B, Moreno RF, et al. Complementary DNA sequencing: expressed sequence tags and human genome project. Science 1991; 252(5013):1651-1656.
85. Wang E, Marincola FM. cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J 2001; 7(1):16-24.
86. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95(25):14863-14868.
87. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14(4):457-460.
88. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24(3):227-235.
89. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406(6797):747-752.
90. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769):503-511.
91. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62(13):3581-3586.
92. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, Lander ES, Hacohen N. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294(5543):870-875.
93. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001; 2(9):882-888.
94. Chtanova T, Kemp RA, Sutherland AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. J Immunol 2001; 167(6):3057-3063.
95. Hamalainen H, Zhou H, Chou W, Hashizume H, Heller R, Lahesmaa R. Distinct gene expression profiles of human type 1 and type 2 T helper cells. Genome Biol 2001; 2(7):RESEARCH0022.
96. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3(7): RESEARCH0035.
97. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 1997; 94(6):2150-2155.
98. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8(5):500-508.
99. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10(5):445-456.
100. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, Karandikar NJ, Casazza JP, Koup RA. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol 2002; 168(6):3099-3104.
101. Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, Rubio-Godoy V, Walker PR, Rimoldi D, Lienard D, Cerottini JC, Romero P, Dietrich PY. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002; 168(8):4231-4240.
102. Lim A, Baron V, Ferradini L, Bonneville M, Kourilsky P, Pannetier C. Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. J Immunol Methods 2002; 261(1-2):177-194.
103. Phillips J, Eberwine JH. Antisense RNA amplification: a linear amplification method for analyzing the mRNA population from single living cells. Methods 1996; 10(3):283-288.
104. Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK. Advantages of mRNA amplification for microarray analysis. Biotechniques 2002; 33(4):906-912, 914.
105. Naour F. Contribution of proteomics to tumor immunology. Proteomics 2001; 1(10):1295-1302.
106. Nagorsen D, Marincola FM. How to analyze ex vivo T cell responses in cancer patients. In Vivo 2002; 16(6):519-525.